In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teijin Pharma Limited.

https://www.teijin-pharma.com/

Latest From Teijin Pharma Limited.

Silence Therapeutics Continues Transformation, Improves US Visibility

The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.


Financing Gene Therapy

OliX Moves Into Spotlight Amid Strong RNAi Interest, New Platform

With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.

South Korea Biologics

Menarini Expands In Cancer With Radius Drug Deal

Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.

Cancer Deals

Invitae And ArcherDX Will Merge To Create Comprehensive Cancer Testing Offering

The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.

Deals Cancer
See All

Company Information

  • Industry
  • Medical Devices
    • Rehabilitation Equipment and Devices
  • Other Names / Subsidiaries
    • MedTech Heart
UsernamePublicRestriction

Register